Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

The tumor microenvironment (TME) includes resident and infiltrative non-tumor cells, as well
as blood and lymph vessels, extracellular matrix molecules, and numerous soluble factors …

Objective To describe clinical and pathological characteristics and treatment outcomes in a
large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design …

Especially given the rarity of aggressive pituitary tumors and carcinomas, and the scarcity of
available data, the ESE guidelines are of tremendous help, providing clinicians with vital …

A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior,
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …

Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic
hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by …

Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality,
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT)
has revolutionised clinical practice in this field with significantly improved clinical outcomes …

Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …